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Abstract 
The greatest proportion of Competitive Intelligence (CI) practice in the pharmaceutical 
industry is located within the R&D function (Halliday et al 1992). This paper reports on the 
results of an empirical study into the infrastructure of competitive intelligence practice within 
the industry.  The study analyses and reports on the results from data and views gathered via 
questionnaire which addressed the questions of attitudes towards CI, methods of gathering CI, 
practitioner background, and problem areas.   
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As a result of the immense pressure placed on pharmaceutical companies to maintain their 
position in a highly dynamic market, there is an urgent requirement for organisations to keep 
abreast of all decision influencing factors, including competitors (Badr et al, 2006, Savioz & 
Sugasawa 2006).  Some 10 years ago, Gilad & Smith (1998) drew attention to the poor state 
of competitor knowledge and competitive intelligence in the pharmaceutical industry and it 
would seem that little has changed. 
 
The significance for R&D practitioners is that many scientists progress into competitive 
intelligence as their business awareness develops and as such, they bring with them unique 
skills which can further benefit the impact that CI can have on the firm's activities.  This is a 
fragmented industry, characterised by many different types of firms which develop, 
manufacture and sell a vast array of products. While the companies themselves may differ, 
they all invest significant sums of money, particularly in research and development (R&D) to 
allow them to compete in the market. 
 
As can be seen from Table 1 below, the top two firms in the UK ranking list of R&D 
expenditure are from the pharmaceutical sector with GlaxoSmithKline spending € 4,564 
million, some 63% more than the second placed firm AstraZeneca with € 2,864 million (EUR 
22348 EN, 2006). 
 
1 GlaxoSmithKline  Pharmaceuticals  € 4,564 million  
2 AstraZeneca   Pharmaceuticals  € 2,864 million 
3 BAE Systems   Aerospace and defence € 2,108 million 
4 BT    Telecommunications  € 1,058 million 
5 Unilever   Food products   €   953 million 
6 Rolls Royce   Aerospace & defence  €   512 million 
7 Royal Dutch Shell  Oil & gas producers  €   498 million 
8 Royal Bank of Scotland Banking   €   478 million 
9 BP    Oil & gas producers     €   425 million 
10 HSBC    Banking   €   356 million 
11 Vodafone   Telecommunications  €   299 million   
12 Marconi/Telent  Telecommunications  €   270 million 
13 Shire    Pharmaceuticals  €   243 million 
14 ICI    Chemicals   €   213 million 
15 Smiths    Aerospace and defence €   209 million 
 
Table 1 - Ranking of UK firms by R&D investment, 2006 
 
As reported by Epsicom (2008) the UK is one of the leading pharmaceutical producers and 
exporters in the world.  There are six main types of firm present in the UK market, the largest 
being global, research based pharmaceutical companies. Typically, these are large size, large 
scale firms with significant R&D investment, complex product portfolios and long product 
pipelines.  These companies have capabilities across all therapeutic areas and usually have 






Medium sized companies tend to be specialists operating in niche markets. Many mid-sized 
firms find it difficult to compete with the large global players and can be prone to acquisition 
by the larger organisations.  Mergers between smaller firms and larger players do sometimes 
take place, but to all intents and purposes the majority of mergers are absorption of the 
smaller firm into the larger corporate body. 
 
Smaller organisations focus on specific research projects, typically biopharmaceutical 
activities.  They are more likely to be funded by government grants or venture capitalists. 
These companies would not normally manufacture their newly developed products but seek to 
licence their intellectual property to larger companies. This further helps to subsidise their 
next project. 
 
Generic pharmaceutical companies do not actively partake in any R&D. They opt for “me 
too” products and cash in when patents expire, typically producing a cheaper alternative. 
 
Consumer Healthcare companies carry out some R&D but concentrate on ‘over the counter’ 
(OTC) products. Many of the large manufacturers also have a consumer healthcare division 
although this would tend to represent a smaller percentage of their overall interest. 
 
Finally, Drug Delivery companies focus on developing novel modes of delivery for 
established products. These include line extensions, and improved formulations. More often 
than not these companies work in partnership with the larger pharmaceutical companies. 
 
Many factors determine the choice and direction of a company’s approach to R&D and 
therefore organisations are continually changing their CI strategy.  In the 1960s the main trend 
of pharmaceutical R&D was towards the evolution of antibiotics (Handfield-Jones, 1965).  
This gave way to research on the central nervous system in the 1980s (Tofilon & Fike, 2000).  
This changed dramatically in the 1990s with the introduction of molecular biology and the 
formulation of various vaccines (Moss, 1991).  R&D’s focus looks set to change again with 
the emergence of biotechnology (Acharya et al, 2003) and the science of genetics (Knoppers 
& Chadwick, 2005, Wensley, 2008) 
 CI in Pharma 
There is a generally held view is that CI is ubiquitous and beneficial to Pharmaceutical  
decision makers.  One would expect to find sophisticated thinking, speed of action, innovative 
analysis and a skill set which went far beyond description and idle speculation.   
 
It is also easy to think that CI in pharma has been heavily researched and that there is little left 
to learn.  Even (blind) reviewers of this paper made comments to this effect.  One reviewer 
said, “In the US, the theme and the industry in question have been in the public gaze (for) 
years”.  Whilst this may be true, no citations were offered to support this opinion, and as this 
study was focused on CI practice in the UK pharmaceutical industry only, this was a mute 
point.  A second reviewer noted that “Author(s) refer to some outdated sources of information 
although both R&D activities and the pharmaceutical industry are, or should be, one of the 
most dynamic business areas”.  The use of the words “should be” is indicative here.  Again, 




covered, when it has not been.  The third reviewer had a converse view and noted that “The 
research method and sample carry conviction and the research offers a comprehensive 
picture of CI activities in pharmaceutical companies in the UK”.  The true extent of published 
and publicly available empirical work in this area, specifically in CI practice in pharma, is that 
it is far from numerous.  Our findings set out in the next section may well be surprising to 
some. 
Theoretical and Empirical Foundation 
The global pharmaceutical market is experiencing unprecedented changes which are adding to 
the competitive nature of the industry and these changes are occurring on a macro and micro 
level (Richardson & Luchsinger 2004, Bickerstaff et al 2006).  A major problem facing the 
industry is a reduction in the amount of product output compared to R&D expenditure and as 
Dyer (2002a) points out, the industry may have reached saturation point in terms of the 
number of elusive ‘blockbuster’ drugs that can be developed.  So, with little promise of 
finding a new ‘blockbuster’ drug, organisations are finding that their product pipelines are 
reducing, yet the cost of R&D is growing (DiMasi & Paquette 2004, Leahy & Neary 2007, 
Becker & Pain 2008).  Coupled with this, is the fact that many of the ‘blockbuster’ drugs 
developed in the 80’s and 90’s are currently coming off patent and as such firms can expect 
stiff competition from the generic level of manufacturers (Dyer, 2002b, Becker & Pain 2008).  
It is within this context that an increased level of CI activity is not only desirable, but 
essential. 
 
In looking at this from an internal, information exchange viewpoint, McMillan et al (1995) 
concluded that "a policy of encouraging openness with scientific information be a superior 
strategy to secrecy, particularly in high-technology companies".  Their model was 
subsequently tested with a longitudinal analysis of 20 large US pharmaceutical firms where it 
was found that 'openness' was a "very strong predictor of R&D performance".  From this it 
would seem that all firms, whether they are high or low technology in nature, need to be 
acutely aware of the information which exists within both their external and internal 
environments.  The impetus then becomes how to use such information (Espositio & Gilmont, 
1991) and to leverage internal knowledge for competitive advantage.  This is particularly 
relevant for high-technology, R&D driven firms, the pharmaceutical sector being a prime 
example of such (McNair & Liebfried, 1993, Krol et al 1993, McMillan & Hamilton, 2000a). 
 
Porter (1980) takes an external environmental perspective to intelligence gathering and argues 
that any executive who is focusing on the future must formulate and answer the following 
questions: 
 
• What is driving competition in my industry? 
• What actions are competitors likely to take and what is the best way to respond 
• How will my industry evolve? 
• How can my firm be best positioned to compete in the long run? 
 
There are many views as to the exact meaning of the term Competitive Intelligence.  Wright 
& Pickton (1998) differentiated between competitive intelligence and competitor intelligence 




decision making process through the gathering and analysing of information, while 
competitor intelligence is the name given to information gathered relating to actual 
competitors.  Here, we are using CI as the collective term for the ‘activity of monitoring the 
competitive landscape in general and competitors in particular’.  McGonagle & Vella (2002) 
identified four distinct categories of CI:  strategic, tactical, technology and target.  The 
characteristics of each are given in Table 2. 
 
McGonagle & Vella (2002) point out that, among others, two critical elements exist in all four 
orientations: 1) common sources of raw date and 2) a common set of tools and approaches 
employed to aid the understanding and interpretation of the raw data. 
 
Type Typical Pharmaceutical Sector Use  
Strategy orientated CI Providing insight into high level decisions on current and 
future strategy, external sense-making, patent tracking, future 
product decisions, sector commitment analysis, nurturing of 
M&A candidates, strategic alliances and joint venture 
partners 
Tactics orientated CI Focuses on current activities and near-term plans in the 
market place, not too distant a cousin of marketing 
intelligence or market research but more orientated toward 
the B2B environment, assessing sales support needs, testing 
of product linkages, improving service levels 
Technology orientated CI Potential for exploitation of opportunities resulting from 
scientific and technical changes to production processes and 
drug delivery methods, highly relevant where R&D and 
technological innovation is a key industry driver and a main 
source competitive advantage.  Technology orientated CI in 
the pharmaceutical sector is key to delivering high returns 
from an efficient and efficient R&D effort 
Target orientated CI  Typically looked at a named set of competitors, assesses their 
competencies, current and likely future activities, 
commitment to market segments, tracks patent applications 
and expiries, engages in game theory, scenarios planning and 
"what if" analyses 
 
Table 2 - Four categories of CI practice 
 
As one of the most competitive sectors in the European economy, with an output value of 
€160 billion, an export value of €95 billion, a trade balance in excess of €30 billion and 
responsible for between 580,000 and 600,000 jobs (European Commission 2005), it might be 
a reasonable expectation that the pharmaceutical industry would be fully aware of all the 
competitive forces around it and have proven processes and procedures whereby information 
on their competitors can be transcribed into meaningful intelligence. 
 
More specifically, by introducing CI procedures, pharmaceutical firms can significantly 





• changes in competitor portfolios 
• competitor R&D investments 
• clinical trial and patent applications 
• M&A activity that could pose a threat 
• positioning of competitive drugs 
• sales policies adopted by medical representatives to major buyers 
• shifting sales structures of competitors 
• changing commercial priorities  
• potential impact of upcoming competing drug launches 
• potential legal pitfalls on own and competing drug launches 
• impact of legislative changes in the global health sector 
Canongia et al (2004) argues that CI, if implemented and used correctly, can confer on the 
company a high degree of ‘technological foresight’. This is an important factor as it ties in 
neatly with the concept of innovation and many theorists believe that to be the only force 
capable of creating appreciable changes in the market.  Canongia et al (2004) also re-states 
the opinion that the pharmaceutical industry is one driven by innovation and technological 
advancement in pursuit of competitive advantage. 
 
The literature available on the application of CI in the pharmaceutical industry is somewhat 
limited although Lichtenthaler (2003) did examine technology intelligence processes.   A 
major conclusion therefore, is that the literature does not address the practicalities of CI in 
terms of the sources used, the type of individuals who are engaged in CI, the departmental 
structure, or the levels of communication between other departments. 
 
Table 3 presents an analysis of scholarly literature using “intelligence” as the first filter, then 
three sub-filters: “pharma”, “R&D”, and “science”.  Short magazine articles, text books and 
duplicates have been removed.  The source for this search was the bibliography and 
categorisation of key CI scholarship produced in four parts by Dishman et al (2003), Fleisher 
et al (2003), Knip et al (2003) and Fleisher et al (2007).  Table 4 presents the primary focus 






Pharma R&D Science Total 
Up to 1989 2 (a) 5 (b) 4 (c) 11 
1990-1996 6 (d) 5 (e) 7 (f) 18 
1997-2003 3 (g) 3 (h) 2 (i) 8 
2003-2006 3 (j) 0 3 (k) 6 
    43 
 









 Primary Focus Authors 
(a) Patents as a forecasting tool 
Bibliometric analysis of US research 
Mlodzik (1979) 
Narin & Rozek (1988) 
(b) Patents and R&D 
Industrial R&D Practice in Japan 
R&D evaluation 
Japanese R&D in the US 
Information Specialists in R&D 
Pakes & Griliches (1980) 
Mansfield (1988) 
Krogh et al (1988) 
Herbert (1989) 
Walton, Dismukes & Browning (1989) 
(c) Foreign Patenting 
Co-Citation Analysis Part 1 
Co-Citation Analysis Part 2 
Proprietary law in biotech research 
Soete & Wyatt (1983) 
Small & Greenlee (1985a) 
Small & Greenlee (1985b) 
Eisenberg (1987) 
(d) R&D Philosophy 
Patent based citation analysis 
Competitive analysis 
CI practice in UK pharma 
Role of the information professional 
Patent analysis 
Halliday, Walker & Lumley (1992) 
Smith & Narin (1993) 
McNair & Liebfried (1993) 
Desai & Bawden (1993a) 
Desai & Bawden (1993b) 
Steele (1994) 
(e) Assessing R&D capability 
Technology fusion and new R&D 
Scientific CI in R&D decision making 
Foreign R&D in the US 
Using R&D to manage competitors 
Klavans & Simon (1990) 
Kodama (1992) 
Krol, Coleman & Bryant  (1996) 
Serapio & Dalton (1993) 
Keiser (1994) 
(f) S&T indicators in strategic planning 
Monitoring S&T development 
S&T scouting 
Monitoring S&T for CI 
S&T evolution 
Scientific openness vs secrecy 
Competitive S&T intelligence 
van der Eerden & Saelens (1991) 
Ashton, Kinsey & Gunn  Jr(1991) 
Bodelle & Jablon (1993) 
Ashton, Johnson & Stacey (1994) 
Mort (1994) 
McMillan, Klavans & Hamilton III (1995)
Albagli, Dawson & Hasnain (1996) 
(g) Information resources 
Lack of competitor intelligence 
Bibliometrics to measure knowledge 
Mullen, Blunck & Moller (1997) 
Gilad & Smith (1998) 
McMillan & Hamilton III. (2000a) 
(h) Assessing an industry’s R&D 
Management of Scientific Information 
Assessing mergers via patent analysis 
Breitzman (2000) 
McMillan & Hamilton III (2000b) 
Breitzman, Thomas & Cheney (2002) 
(i) S&T Mapping 
Science of business intelligence 
Kopcsa & Schiebel (1998) 
O’Guin & Ogilvie (2001) 
(j) Stakeholder issues in biopharma 
CI practice in South African pharma 
CI and decision making in pharma 
Nystrom & Lalanyee (2003) 
Muller (2004) 
Badr, Madden & Wright (2006) 
(k) S&T capability 
Tools for IS&T analysis 
Managing S&T intelligence 
Lane & Klavans (2005) 
Fleisher (2006) 
Savioz & Sugasawa (2006) 
 





The work of Desai & Bawden (1993a) looked at the application of CI in UK pharmaceutical 
firms.  Their small scale study of 10 firms focused on the provision of CI within their sample 
and in particular the role of the CI professional.  Their results indicated that 5 firms located 
the activity within the R&D function, 2 in Finance, 1 in Intellectual Property and 1 in Medical 
and Human Health Divisions. Interestingly, only 1 company indicated that they had a 
dedicated CI unit. With regard to staff, 6 of the respondents indicated that they had specialist 
CI staff, while the remaining 4 had a variety of staff from different disciplines who undertook 
CI activity, as and when required. Of the 4 which didn’t have specialist staff, only 1 indicated 
that their firm would like to have specialist CI staff in the future.  The types of sources used 
included sales figures, product portfolios, R&D portfolios, market information, company 
information and press sources. 
Objectives and Methodology 
The conclusion to be reached from the previous discussion is that there is an obvious gap in 
the body of knowledge regarding the opinions and practices of CI in the pharmaceutical 
Industry.  While the literature indicates that the industry does use CI and that it is effective, 
there is little evidence which describe the exact practices which occur. Therefore, this study 
aimed to identify the current status of CI in the UK Pharmaceutical Industry and was 
formulated around the following objectives: 
 
1) To identify the current status of CI activity in the industry 
2) To identify the type of individual who is responsible for carrying out CI activities, 
including academic and employment background 
3) To identify the most commonly used sources of CI in the industry 
4) To identify the tools and techniques used to analyse CI 
5) To examine the views of senior managers towards the practice and benefits of CI 
6) To assess the impact of CI on other functional business departments 
Population Identification 
All UK pharmaceutical companies were identified using the FAME database and the SIC 
codes for ‘research and development of pharmaceutical products’ (Code 73.0) and 
‘manufacturing of pharmaceutical products’ Code (24.4) as identifiers. From an original 
sample of 508 companies, filters were applied to remove subsidiaries of other firms.  Several 
updates were run, the final one being immediately prior to despatch of the survey instrument 
and this revealed that 59 firms had ceased to trade. 
Sample Size 
A qualified sample of 196 firms constituted was identified.  All firms listed contact details for 
the Marketing function and in a desire to have a common sample and a greater chance of the 
individual being both aware of the organisation’s competitive activities, this contact level was 
selected.  Following a reminder, a total of 53 questionnaires were received which represented 
an acceptable response rate of 23 per cent.  
 






Turnover n  Employees n 
< £1 billion 31  > 1000 30 
£501m - £1bn 4  501 - 1000 10 
£251m - £500m 0  251 - 500 2 
£101m - 250m  3  100- 25- 7 
< £100m 15  <100 4 
Total 53   53 
 
Table 5 - Characteristics of responding firms 
Survey Instrument 
A self completion, structured questionnaires of 24 items was administered to the sample size.   
 
Ideally, this method would be combined with ethnography so that the researcher could 
actually spend time with the managers who carry out CI activities.  The benefits of this 
approach would be that the researcher could get insight into the beliefs, opinions and 
capabilities of CI managers from their point of view as well as observe the relationship 
between CI and other business functions.  It was not anticipated that managers would not 
agree to this and the constraints of the study did not permit such an approach. 
 
A contact list of all the pharmaceutical companies in the UK was obtained using the FAME 
database using SIC code for ‘research and development of pharmaceutical products’ and 
‘manufacturing of pharmaceutical products’ as identifiers.  This first returned a sample of 508 
companies.  The necessary vetting process revealed that several entries were subsidiaries of 
other companies with identical trading addresses, and the update showed that 59 had ceased to 
trade.  Consequently, 196 firms constituted the final sample.  Whilst all firms had contact 
details from CEO level down, each company showed contact details for the Marketing 
Executive.  It was then deemed desirable to take a common sample of such executives.  It was 
also thought that such an individual would have a greater chance of being aware of the 
organisation’s competitive activities and would at least be interested in participating. 
 
Despite response rates for postal questionnaires usually being low, the sensitivity of the 
research topic suggested that this method of enquiry, with the promise of anonymity if 
desired, would provide respondents with a level of comfort they might need in encourage 
them to disclose their views. 
 
The questionnaire was ‘structured’ in nature and consisted of 24 questions, 23 of which were 
‘closed’ with the respondent choosing between possible answers using a Likhert scale.  One 
question was ‘open’ where the respondent was free to respond in their own words (Wright & 
Crimp 2000). Questions 1-3 focused on providing a general overview of the organisations CI 
activities in terms of the name they actually gave to the process.  
 
Questions 4-8 focused on the type of individual who usually carried out CI activities.  The 
questions included enquiring about their current and previous job titles, special areas, length 
of time involved in CI and their CI training record. The purpose of these questions was to 




wholly dependant on R&D it was important to determine if these individuals are more likely 
to be involved in CI activities as opposed to the traditional view of CI being integrated into 
the wider business function.  
 
Questions 9-15 focused on the practical aspects of CI and related to the acquisition, 
accessibility, storage and dissemination of CI as demonstrated in the CI cycle.  Questions 16 – 
19 related to the attitudes and contributions of other individuals in the organisation to the CI 
process from senior management level to other functional levels.  Questions 18-23 aimed to 
classify the company by size to help facilitate the analysis of results and draw comparisons 
between large, medium and small scale organisations. 
 
The final open question, asked respondents to give their personal opinions as to the future 
development of CI in the UK pharmaceutical industry. At the conclusion of each 
questionnaire, respondents were asked if they would be willing to take part in a 10 minute 
telephone interview. The aim of this was to capitalise on those respondents who wished to 
expand on their views thereby adding greater depth to the results. Respondents were also 
offered an executive summary of the results.  Each questionnaire was accompanied by a cover 
letter which explained who the researcher was and the purpose of the research.  
 
Questions 1, 2, 7, 9, 10, 11, 12, 13 and 14 were adapted from Badr (2003) and questions 16, 
17 and 19 were adapted from Wright et al (2002) 
 
Three copies of the questionnaire were sent to the 196 firms identified as a relevant sample.  
Following a reminder, a total of 53 questionnaires were received which represented an 
acceptable response rate of 23 per cent.  In depth telephone interviews were carried out with 
those who had indicated a willingness to take part.  Telephone interviewing was preferred due 
to time constraints for both parties and the geographical location of the willing respondents.  
The interviews were semi-structured in nature where a list of topic areas was prepared 
beforehand in order to direct the flow of the conversation but the respondents were allowed to 
develop their ideas and speak widely on issues of interest.  This approach was successful as 
the event proved comfortable for both the interviewee and the researcher. 
Headline findings 
The key findings from this study are given in Table 6 below and the links between questions 
asked and the objectives of the study are also provided. 
 
Objective Element Common Response Given % 
1 Name given to intelligence gathering 
activities 
Competitive intelligence 47.2% 
1 Current status of CI in your 
organization 
Intend to develop separate 
CI function 
37.7% 
1 Longevity of carrying out  CI Between 5-7 years 30.2% 
1 Reason for practicing CI Industry awareness 90.6% 
2 Current job title Marketing manager 28.3% 






2 Specialist area of expertise Science  45.3% 
2 Formal Training in CI None 49.1% 
2 CI education Personal reading 60.4% 
3 Sources used for CI  - positive Customers (sometimes)  49.1% 
3 Sources used for CI - negative Consultants (rarely) 39.6% 
4 Analytical techniques used - positive SWOT (often) 34.0% 
4 Analytical techniques used - negative War games/role playing 
(never) 
67.9% 
5 Senior managers' views of CI - positive CI is an essential input to 
SDM 
83.0% 
5 Senior managers' views of CI - negative CI makes little measurable 
contribution 
56.6% 
6 View of other departments towards CI - 
positive 
CI was good for the 
company’s situation 
58.5% 
6 View of other departments towards CI - 
negative 
CI incurs more work for us 47.2% 
 
Table 6 - Key findings and relationship to objectives 
Conclusions 
In linking back to the original research objectives it can be seen that the current state of CI 
practice is fragmented and embryonic.  The background and experience of those practicing CI 
comes largely from marketing, IT, technology and R&D.  The sources and analytical tools 
most used by practitioners were customers, suppliers and distributors.  Least often used were 
consultants and social contacts.  In terms of analysis, SWOT dominated.  Close behind was 
nothing more sophisticated than CSF analysis, competitor profiling and financial analysis.  
Finally, the views of both senior management and other departments of the contribution 
which CI made to the firm's overall progress were mixed.   Most commonly, respondents 
thought that other departments accepted CI was of good use to the company’s situation, but a 
significant number reported that other departments believed that the practice of CI only 
incurred more work for them.  
 
It is clear that until and unless, all functions within the firm learn to co-operate, cross-fertilise 
and engage in collaborative learning, a fully fledged CI function will struggle to emerge.  It is 
about understanding what CI activity in an R&D driven environment can do for the firm and 
appreciating the contribution which intelligence can bring to the decision making table. 
 
It is also about capitalising on all the many sources of human and technical intelligence 
residing within the firm and actively managing this for the common good.  CI is an activity 
that has been embraced wholeheartedly by other key industries such as consumer goods, 
telecommunications, engineering and even service industries.  From the evidence of this study 
it is quite amazing that pharmaceutical firms, given their devotion to technological 
advancement and absolute requirement to capitalise on knowledge, are lagging behind in the 





It is just possible that big pharma may not be quite as “intelligent” as many of its observers 
would like to think.  Maybe the industry is falling into the trap of actually believing its own 
publicity, thinking that the super-charged world they live in is reality, and that the industry is 
indestructible.  Time will tell, but with the economic pressures which are to be faced in 2009 
and beyond, it would certainly be wise for pharmaceutical firms to put as much effort into 
developing a sophisticated and robust approach to its intellectual assets as it does to its brand 
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